CervoMed Inc. (CRVO)

CervoMed Inc. (CRVO) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $35.4M; returns 1 day +3.1%, 1 week +3.1%, 1 year -67.4%.

CervoMed Inc. (CRVO) is a biopharmaceutical company focused on developing innovative therapies for neurodegenerative diseases, particularly dementia with Lewy bodies (DLB). Their primary product candidate is neflamapimod, which is currently in Phase 2b clinical trials.

Groups CRVO belongs to

• Biotechnology
• Clinical Stage Biotech
• Neuroscience
• Neurological Disorders
• Healthcare
• CNS Disorders
• Life Sciences
• Biopharmaceutical
• R&D
• Clinical Stage
• Aging Population Needs
• Pharmaceuticals
• Healthcare Innovation

CRVO financial model: income statement, cash flow and balance sheet